- Policy & Regulation
- Regional Views
- Regulatory Trackers
- Pink Sheet Originals
- Featured Topics
Latest From Tara Hansen
Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?
Bookmark
-
Analysis
US FDA’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six next week. Over the next two years, an additional five indications may be up for review.
Advertisement
Susan Hunneyball
Email Author
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.